13 August 2015 - Hospira, Inc. applauds the UK's National Institute for Health and Clinical Excellence (NICE) for developing and issuing a new adoption resource to further support the introduction of biosimilar infliximab, including Hospira's Inflectra, allowing patients greater access to these expensive treatments and greater choice for physicians.

The recently published adoption resource entitled, "Introducing biosimilar versions of infliximab: Inflectra and Remsima," provides practical advice on how to effectively introduce biosimilars into clinical practice, as well as a process to implement a well-managed and safe switching program from reference biologics to biosimilars. Through case studies, the resource highlights how biosimilars can help lead to a more sustainable healthcare system and can help improve patient access to high cost biologic medicines.

This new resource underlines the opportunities for cost-savings and re-investment, stating that "the use of biosimilars can reduce costs, allowing more treatment with new medicines as long as the appropriate follow-up and monitoring systems are in place to manage risk and patient needs and expectations." According to NICE, "Biosimilars have the potential to offer the NHS considerable cost savings, especially as biological medicines are often expensive and are often used to treat long-term conditions."

For more details, go to: http://phx.corporate-ir.net/phoenix.zhtml?c=175550&p=irol-newsArticle&ID=2079343